Author

H. Wheat

Observed names: H Wheat, Hollie Wheat

OpenAlex ID: A5046932679

Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK

2024 · Rachael Batteson, Emma Hook, et al. · Targeted Oncology · 3

CO23 Validating the Results of a Matching Adjusted Indirect Comparison (MAIC) in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC)

2022 · A Hatswell, R Batteson, et al. · Value in Health · 1

EE48 Cost-Effectiveness of Tepotinib Versus Docetaxel Monotherapy for Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Harboring METex14 Skipping in Finland

2024 · E Karttunen, S Jääskeläinen, et al. · Value in Health

EE372 Modeling the Cost-Effectiveness in a Sub-Population: Tepotinib Versus Chemoimmunotherapy (C+IO) in Untreated Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METEX14) Skipping

2023 · R. Batteson, H. Vioix, et al. · Value in Health

SA22 Tepotinib Versus Chemotherapy in Met Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC): Real-World Evidence (RWE) and Matching-Adjusted Indirect Comparison (MAIC) to Explore the Impact of Subsequent Therapy

2023 · H. Wheat, A. Hatswell, et al. · Value in Health

EE146 Cost-effectiveness of Tepotinib for Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Harboring Metex14 Skipping Alterations in Spain

2023 · E. Arriola, R. Batteson, et al. · Value in Health

Postpartum hemolytic uremic syndrome in a patient with preexisting hypertension and resolving preeclampsia

2007 · J.S. Karam, P. Pitiranggon, et al. · Clinical Nephrology

Works count: 7

Citation count: 4

H-index: 1

I10-index: